Biobeat

Company Overview

Snapshot

Founded in March 2016 by Arik Ben Ishay, Johanan May, and Israel Sarussi, Biobeat operates with 11–50 employees. The company has raised $68.6M across 7 funding rounds from 7 investors. In January 2026, Biobeat secured Series B funding with Ally Bridge Group as a lead investor.

Business overview

Biobeat is a med-tech company that provides FDA-cleared, cuffless blood pressure monitoring solutions. Its core technology utilizes a proprietary patented PPG sensor embedded in a small, non-invasive sensor placed on the patient’s chest for 24 hours. This device not only measures blood pressure but also extracts heart rate and cardiac output. The company serves the health tech and life sciences sectors, offering an automated platform that delivers detailed reports to clinicians, facilitating quick evaluation and treatment plans. Biobeat's solution aims to eliminate white coat and masked hypertension by allowing patients to undergo monitoring without the stress associated with traditional cuff-based devices.

Strategic signal

In March 2024, Biobeat's blood pressure patch was highlighted by news outlets, signaling a growing market acceptance and public awareness of its innovative cuffless technology. This indicates a positive trajectory for the company in expanding its reach and validating the utility of its non-invasive monitoring solutions in everyday healthcare, potentially attracting further investment and partnerships in the remote patient monitoring space.

Company Intelligence Q&A

When was Biobeat founded?

Biobeat was founded in March 2016 by Arik Ben Ishay, Johanan May, and Israel Sarussi.

What is Biobeat's primary offering?

Biobeat provides FDA-cleared, cuffless blood pressure monitoring using a small, non-invasive sensor that also measures heart rate and cardiac output.

Has Biobeat received any regulatory approvals for its technology?

In March 2022, the FDA cleared Biobeat's remote vital sign monitoring system. Additionally, in August 2019, the FDA approved Biobeat's patch and watch devices.

What was a significant recent funding event for Biobeat?

In January 2026, Biobeat secured Series B funding, with Ally Bridge Group leading the round and OrbiMed also participating.

What is the total capital raised by Biobeat?

Biobeat has raised a total of $68.6M across 7 funding rounds.